MAY 24, 2019 2:36 PM PDT

New Therapeutic Target for Depression

WRITTEN BY: Nouran Amin

In a study published in the Journal of Psychopharmacology, a new drug target for the treatment of depression has been identified by researchers at the Department of Human Physiology of the UMA Faculty of Medicine.

The study stemmed from the research group, “Neurochemistry of the Transmission in the Central Nervous System”, co-directed by Professor Zaida Díaz-Cabiale, where they identified ‘GAL (1-15)’--part of the neuropeptide molecule called Galanin.

Galanin is central to the common symptom of depression—anhedonia, the loss of pleasure in daily activities.

“We have verified through different experiments how animals modify their response to high-reinforcement appetitive stimuli, such as saccharine or sexual attraction, after the administration of the Galanin fragment”, explains researcher Carmelo Millón, one of the authors of this study. “The understanding of these mechanisms opens the way for endless therapeutic strategies, hence its importance.”

Researchers from Karolinska Institute in Sweden also collaborated on the study and examined the molecular interactions of brain reinforcement system. They observed that the brains' ability to support positive behavior was inhibited by the Galanin fragment which reaffirmed the initial findings.

Most therapeutics for depression are SSRIs (selective serotonin reuptake inhibitors)—such drugs can take up to two weeks to start showing signs of treatment with a further 30 percent of patients who receive the medication are resistant to the treatment.

Learn more about the future of depression treatments:

Source: Drug Target Review

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 10, 2020
Drug Discovery & Development
FDA Approves New Antibiotic for Hospital-Acquired Pneumonia
JUN 10, 2020
FDA Approves New Antibiotic for Hospital-Acquired Pneumonia
The US Food and Drug Administration (FDA) has approved Recarbrio, an antibiotic drug created by pharmaceutical company M ...
JUN 13, 2020
Neuroscience
High Doses of Ketamine Can Switch Off the Brain
JUN 13, 2020
High Doses of Ketamine Can Switch Off the Brain
Researchers from the University of Cambridge, England, have found that high doses of ketamine temporarily switch off the ...
JUN 15, 2020
Drug Discovery & Development
New Antibiotic 'Irresistin' Defeats All Resistant Bacteria
JUN 15, 2020
New Antibiotic 'Irresistin' Defeats All Resistant Bacteria
Researchers from Princeton University have identified a compound capable of killing both Gram-positive and Gram-negative ...
JUL 17, 2020
Drug Discovery & Development
Could Low-Dose Radiation Therapy Treat COVID-19?
JUL 17, 2020
Could Low-Dose Radiation Therapy Treat COVID-19?
Research from a century ago points towards the potential of low-dose radiation therapy (LDRT) for treating pneumonia. Ev ...
JUL 20, 2020
Cancer
Fighting Cancer with Black Pepper
JUL 20, 2020
Fighting Cancer with Black Pepper
In the never-ending search for the next treatment or cure, many researchers turn towards nature. The study of black pepp ...
JUL 14, 2020
Drug Discovery & Development
How Cancer Cells Influence Drug Responses
JUL 14, 2020
How Cancer Cells Influence Drug Responses
When studying a large number of brain samples, researchers were able to characterize how changes in cells influence drug ...
Loading Comments...